CTMX on Nasdaq

CytomX Therapeutics, Inc.

American pharmaceutical preparations company based in South San Francisco.

Price unavailable

Last updated Oct 18, 2026.

Overview

$76.2MRevenue, fiscal 2025²

-$17.4MNet income, fiscal 2025²

Compare with AbCellera Biologics Inc., OMEROS CORP or Eton Pharmaceuticals, Inc., or pick any stock.

TickerCTMX on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersSouth San Francisco, United States
Incorporated inDE³
Business address151 Oyster Point Blvd., Suite 400, South San Francisco, Ca 94080³
Filer categoryAccelerated filer³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-29.3%Operating margin²

-22.8%Net margin²

-44.8%Revenue growth, 2025²

-17.5%Return on equity²

-$75.8MFree cash flow²

Where the money goes

Where each dollar of revenue went, fiscal 2025

Research and development

Research and development90¢$68.7M
Other costs9¢$7.2M
Income tax0¢$238.0K

Out of $76.2M in revenue.² The company lost money this year.

Financial statements

Revenue⁴⁵⁶⁷⁸²$76.2M in 2025+28% since 2018

Operating income⁴⁵⁶⁷⁸²-$22.4M in 2025−71% since 2018

Net income⁴⁵⁶⁷⁸²-$17.4M in 2025−79% since 2018

Every line of the income statement as filed: the last 2 fiscal years, latest first.²

Period ending	2025-12-31	2024-12-31
Revenue	$76.2M	$138.1M
Research and development	$68.7M	$83.4M
General and administrative	$29.8M	$29.7M
Total operating expenses	$98.6M	$113.1M
Income (loss) from operations	-$22.4M	$25.0M
Interest income	$5.2M	$7.1M
Other income (expense), net	$28.0K	-$38.0K
Income (loss) before income taxes	-$17.1M	$32.1M
Provision for income taxes	$238.0K	$224.0K
Net income (loss)	-$17.4M	$31.9M
Net income (loss)	-$17.4M	$31.9M
Deemed dividend on warrants	-$3.0M	$0
Net income (loss) attributable to common stockholders	-$20.4M	$31.9M
Unrealized gain (loss) on available-for-sale investments, net of tax	$84.0K	-$68.0K
Total comprehensive income (loss)	-$17.3M	$31.8M
Net income (loss) per share, Basic	-$0	$0
Net income (loss) per share, Diluted	-$0	$0
Shares used to compute net income (loss) per share, Basic	137.9M shares	84.4M shares
Shares used to compute net income (loss) per share, Diluted	137.9M shares	84.7M shares

Total assets¹¹⁴⁵⁶⁷⁸²$151.6M in 2025−67% since 2018

Total liabilities¹¹⁴⁵⁶⁷⁸²$52.6M in 2025−84% since 2018

Shareholders’ equity⁵⁶⁷⁸²$99.0M in 2025−27% since 2018

Cash¹¹⁵⁶⁷⁸²$12.7M in 2025−95% since 2018

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.²

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$12.7M	$38.1M
Short-term investments	$124.4M	$62.6M
Accounts receivable	$2.0M	$3.1M
Prepaid expenses and other current assets	$4.9M	$3.6M
Total current assets	$143.9M	$107.3M
Property and equipment, net	$1.3M	$2.5M
Intangible assets, net	$438.0K	$583.0K
Goodwill	$949.0K	$949.0K
Restricted cash	$1.5M	$1.0M
Operating lease right-of-use asset	$3.4M	$8.1M
Other assets	$31.0K	$66.0K
Total assets	$151.6M	$120.5M
Accounts payable	$1.3M	$1.1M
Accrued liabilities	$14.2M	$12.3M
Operating lease liabilities - short term	$4.2M	$5.1M
Deferred revenue, current portion	$26.9M	$67.2M
Total current liabilities	$46.6M	$85.8M
Deferred revenue, net of current portion	$1.6M	$26.9M
Operating lease liabilities - long term	$0	$4.2M
Other long-term liabilities	$4.4M	$4.1M
Total liabilities	$52.6M	$121.0M
Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding	$0	$0
Common stock, $0.00001 par value; 300,000,000 and 150,000,000 shares authorized, and 170,186,365 and 80,099,889 shares issued and outstanding at December 31, 2025 and 2024, respectively	$2.0K	$1.0K
Additional paid-in capital	$810.8M	$691.1M
Accumulated other comprehensive income	$111.0K	$27.0K
Accumulated deficit	-$711.9M	-$691.6M
Total stockholders' equity (deficit)	$99.0M	-$456.0K	-$47.4M
Total liabilities and stockholders' equity (deficit)	$151.6M	$120.5M
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300.0M shares	150.0M shares
Common stock, shares issued	170.2M shares	80.1M shares
Common stock, shares outstanding	170.2M shares	80.1M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$12.7M	$38.1M
Short-term investments	$124.4M	$62.6M
Accounts receivable	$2.0M	$3.1M
Prepaid expenses and other current assets	$4.9M	$3.6M
Total current assets	$143.9M	$107.3M
Property and equipment, net	$1.3M	$2.5M
Intangible assets, net	$438.0K	$583.0K
Goodwill	$949.0K	$949.0K
Restricted cash	$1.5M	$1.0M
Operating lease right-of-use asset	$3.4M	$8.1M
Other assets	$31.0K	$66.0K
Total assets	$151.6M	$120.5M
Accounts payable	$1.3M	$1.1M
Accrued liabilities	$14.2M	$12.3M
Operating lease liabilities - short term	$4.2M	$5.1M
Deferred revenue, current portion	$26.9M	$67.2M
Total current liabilities	$46.6M	$85.8M
Deferred revenue, net of current portion	$1.6M	$26.9M
Operating lease liabilities - long term	$0	$4.2M
Other long-term liabilities	$4.4M	$4.1M
Total liabilities	$52.6M	$121.0M
Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding	$0	$0
Common stock, $0.00001 par value; 300,000,000 and 150,000,000 shares authorized, and 170,186,365 and 80,099,889 shares issued and outstanding at December 31, 2025 and 2024, respectively	$2.0K	$1.0K
Additional paid-in capital	$810.8M	$691.1M
Accumulated other comprehensive income	$111.0K	$27.0K
Accumulated deficit	-$711.9M	-$691.6M
Total stockholders' equity (deficit)	$99.0M	-$456.0K	-$47.4M
Total liabilities and stockholders' equity (deficit)	$151.6M	$120.5M
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300.0M shares	150.0M shares
Common stock, shares issued	170.2M shares	80.1M shares
Common stock, shares outstanding	170.2M shares	80.1M shares

Cash from operations⁴⁵⁶⁷⁸²-$75.6M in 2025+0% since 2018

Capital spending⁴⁵⁶⁷⁸²$220.0K in 2025−94% since 2018

Free cash flow⁴⁵⁶⁷⁸²-$75.8M in 2025−4% since 2018

Every line of the cash flow as filed: the last 2 fiscal years, latest first.²

Period ending	2025-12-31	2024-12-31
Net income (loss)	-$17.4M	$31.9M
Amortization of intangible assets	$146.0K	$146.0K
Depreciation and amortization	$1.2M	$1.6M
Impairment loss on machinery and equipment	$402.0K	$106.0K
Accretion of discounts on short-term investments	-$2.2M	-$5.3M
Stock-based compensation expense	$6.3M	$7.7M
Non-cash lease expense	$4.5M	$4.1M
Accounts receivable	$1.1M	$329.0K
Prepaid expenses and other assets	-$1.2M	$1.4M
Accounts payable	$221.0K	-$297.0K
Accrued liabilities and other long-term liabilities	-$3.0M	-$9.6M
Deferred revenue	-$65.6M	-$118.3M
Net cash used in operating activities	-$75.6M	-$86.2M
Purchases of property and equipment	-$220.0K	-$310.0K
Purchases of short term investments	-$192.5M	-$155.5M
Maturities of short term investments	$133.0M	$255.5M
Net cash provided by (used in) investing activities	-$59.7M	$99.7M
Proceeds from issuance of pre-funded warrants and warrants, net of issuance cost	$0	$0
Proceeds from issuance of common stock, net of issuance cost	$109.6M	$6.9M
Proceeds from employee stock purchase plan and exercise of stock options	$811.0K	$613.0K
Net cash provided by financing activities	$110.4M	$7.5M
Net increase (decrease) in cash, cash equivalents and restricted cash	-$24.9M	$21.0M
Purchases of property and equipment in accounts payable and accrued liabilities	$0	$8.0K
Deemed dividend on warrants	$3.0M	$0

Compare CytomX Therapeutics, Inc. with another company

Leadership

Who has led CytomX Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Sean A. McCarthy2015–now

President

Sean A. McCarthy2015–2022

Chief financial officer

20202025

Chief executive officerSean A. McCarthy Oct 7, 2015 to now¹²
PresidentSean A. McCarthy Oct 7, 2015 to Jul 21, 2022¹²
Chief financial officerChristopher Ogden Jun 14, 2024 to now¹³
Chief financial officerJeffrey B. Landau Mar 20, 2023 to Mar 20, 2023¹⁴
Chief financial officerCarlos Campoy Mar 25, 2020 to Mar 20, 2023¹⁵
Chief financial officerDebanjan Ray May 18, 2017 to Jan 29, 2019¹⁶
Chief financial officerRobert C. Goeltz Ii. Oct 7, 2015 to May 16, 2017¹⁷

Board members and other officers (27)

Chief Business OfficerRachael Lester Oct 29, 2025 to now¹⁸
SVP, Chief Scientific OfficerMarcia Belvin Mar 29, 2023 to now¹⁹
Chief Medical OfficerYu-Waye Chu Jul 20, 2023 to now²⁰
OfficerChristopher Ogden Mar 9, 2022 to Mar 21, 2024²¹
Chief Business OfficerJeffrey B. Landau Mar 28, 2022 to Aug 22, 2024²²
Chief Medical OfficerAlison L. Hannah Feb 5, 2020 to Jul 21, 2022²³
Principal Accounting OfficerRobin Knifsend May 31, 2019 to Feb 21, 2020²⁴
Chief Medical OfficerRachel Humphrey Oct 7, 2015 to Jan 29, 2019²⁵
CSO, Head Res.&Non-Clin. Dev.William Michael Kavanaugh Oct 7, 2015 to Feb 19, 2020²⁶
Board memberZhen Su Mar 22, 2024 to now²⁷
Board memberAlan Ashworth Oct 7, 2021 to now²⁸
Board memberHalley E. Gilbert Apr 29, 2020 to now²⁹
Board memberMani Mohindru Dec 18, 2020 to now³⁰
Board memberJames R. Meyers Dec 27, 2018 to now³¹
Board memberMarion McCourt Mar 31, 2017 to Jun 22, 2017³²
Board memberCharles S. Fuchs Oct 24, 2017 to now³³
Board memberJohn A. Scarlett Jun 13, 2016 to Jun 17, 2021³⁴
Board memberHoyoung Huh Jun 14, 2016 to Jun 15, 2018³⁵
Board memberElaine Jones V. Oct 7, 2015 to now³⁶
Board memberIx L.p. Canaan Oct 7, 2015 to Mar 28, 2017³⁷
Board memberMatthew P. Young Oct 7, 2015 to now³⁸
Board memberNeil Exter Oct 7, 2015 to Jun 22, 2017³⁹
Board memberSean A. McCarthy Oct 7, 2015 to now¹²
Board memberTimothy M. Shannon Oct 7, 2015 to Dec 1, 2016⁴⁰
General counselAlejandra Carvajal Aug 5, 2026 to now⁴¹
General counselLloyd A. Rowland Jun 15, 2018 to now⁴²
General counselCynthia J. Ladd Oct 7, 2015 to Jan 27, 2017⁴³

Timeline

Oct 7, 2015New chief executive Sean A. McCarthy becomes CEO¹²
Sep 16, 2010Founded CytomX Therapeutics, Inc. is founded⁴⁴

Filings

317 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 53 major events, 143 insider forms, 59 large holders, 1 private raises, 40 other. The latest 20:

Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 7, 2026SCHEDULE 13G EDGAR
Aug 6, 2026S-8 EDGAR
Aug 6, 20268-K EDGAR
Aug 6, 202610-Q EDGAR
Aug 5, 20264 EDGAR
Aug 5, 20263 EDGAR
Aug 3, 2026SCHEDULE 13G EDGAR
Jul 30, 20264 EDGAR
Jul 30, 20263 EDGAR
Jul 27, 2026SCHEDULE 13G EDGAR
Jul 27, 20268-K EDGAR
Jun 22, 20264 EDGAR
Jun 22, 20264 EDGAR
Jun 22, 20264 EDGAR
Jun 22, 20264 EDGAR
Jun 22, 20264 EDGAR
Jun 22, 20264 EDGAR
Jun 22, 20264 EDGAR

The 317 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 59 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Jun 29, 2023Raised $30 million in a private offering of securities Form D: 4 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Fmr LLC	32,714,937	$122.7M	0.0%	+759,300
Kynam Capital Management, LP	21,703,093	$81.4M	4.5%	+6,690,000
BlackRock, Inc.	17,559,822	$65.8M	0.0%	+12,331,542
Bank Of America Corp /de/	15,082,617	$56.6M	0.0%	+4,879,832
State Street Corp	11,747,236	$44.1M	0.0%	+6,083,828
Perceptive Advisors LLC	10,439,185	$39.1M	0.6%	+340,361
Vanguard Capital Management LLC	8,525,457	$32.0M	0.0%	−207,661
Point72 Asset Management, L.P.	7,811,033	$29.3M	0.0%	−64,357
Wellington Management Group Llp	5,168,961	$19.4M	0.0%	+1,585,976
Venrock Adviser, LLC	4,982,124	$18.7M	0.6%	−5,000,000
Baker Bros. Advisors LP	4,975,826	$18.7M	0.1%	No change
Geode Capital Management, LLC	4,678,716	$17.5M	0.0%	+2,612,104
Elmind Capital, LP	4,550,000	$17.1M	4.3%	No change
Nextech Invest Ltd.	4,449,932	$16.7M	0.8%	No change
Two Sigma Investments, LP	4,132,643	$15.5M	0.0%	+1,422,487
Eversept Partners, LP	3,558,497	$13.3M	0.7%	+369,983
UBS Group AG	3,468,359	$13.0M	0.0%	+348,204
Siren, L.L.C.	3,457,711	$13.0M	0.3%	No change
ADAR1 Capital Management, LLC	3,365,118	$12.6M	0.6%	−45,072
Citadel Advisors LLC	3,110,509	$11.7M	0.0%	−2,295,684
Marshall Wace, Llp	3,024,351	$11.3M	0.0%	−1,113,825
Woodline Partners LP	2,040,210	$7.7M	0.0%	+39,385
Goldman Sachs Group Inc	2,003,652	$7.5M	0.0%	+543,813
Dimensional Fund Advisors LP	1,860,290	$7.0M	0.0%	−70,630
Qube Research & Technologies Ltd	1,824,564	$6.8M	0.0%	−425,019

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARCytomX Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARCytomX Therapeutics, Inc. 10-K for fiscal 2025
3
SEC EDGARCytomX Therapeutics, Inc. filings on SEC EDGAR
4
SEC EDGARCytomX Therapeutics, Inc. 10-K for fiscal 2018
5
SEC EDGARCytomX Therapeutics, Inc. 10-K for fiscal 2019
6
SEC EDGARCytomX Therapeutics, Inc. 10-K for fiscal 2021
7
SEC EDGARCytomX Therapeutics, Inc. 10-K for fiscal 2022
8
SEC EDGARCytomX Therapeutics, Inc. 10-K for fiscal 2023
9
SEC EDGARCytomX Therapeutics, Inc. 10-Q for fiscal 2026
10
SEC EDGARCytomX Therapeutics, Inc. 10-Q for fiscal 2026
11
SEC EDGARCytomX Therapeutics, Inc. 10-K for fiscal 2018
12
SEC EDGARSean A. McCarthy, Chief executive officer
13
SEC EDGARChristopher Ogden, Chief financial officer
14
SEC EDGARJeffrey B. Landau, Chief financial officer
15
SEC EDGARCarlos Campoy, Chief financial officer
16
SEC EDGARDebanjan Ray, Chief financial officer
17
SEC EDGARRobert C. Goeltz Ii., Chief financial officer
18
SEC EDGARRachael Lester, Chief Business Officer
19
SEC EDGARMarcia Belvin, SVP, Chief Scientific Officer
20
SEC EDGARYu-Waye Chu, Chief Medical Officer
21
SEC EDGARChristopher Ogden, Officer
22
SEC EDGARJeffrey B. Landau, Chief Business Officer
23
SEC EDGARAlison L. Hannah, Chief Medical Officer
24
SEC EDGARRobin Knifsend, Principal Accounting Officer
25
SEC EDGARRachel Humphrey, Chief Medical Officer
26
SEC EDGARWilliam Michael Kavanaugh, CSO, Head Res.&Non-Clin. Dev.
27
SEC EDGARZhen Su, Board member
28
SEC EDGARAlan Ashworth, Board member
29
SEC EDGARHalley E. Gilbert, Board member
30
SEC EDGARMani Mohindru, Board member
31
SEC EDGARJames R. Meyers, Board member
32
SEC EDGARMarion McCourt, Board member
33
SEC EDGARCharles S. Fuchs, Board member
34
SEC EDGARJohn A. Scarlett, Board member
35
SEC EDGARHoyoung Huh, Board member
36
SEC EDGARElaine Jones V., Board member
37
SEC EDGARIx L.p. Canaan, Board member
38
SEC EDGARMatthew P. Young, Board member
39
SEC EDGARNeil Exter, Board member
40
SEC EDGARTimothy M. Shannon, Board member
41
SEC EDGARAlejandra Carvajal, General counsel
42
SEC EDGARLloyd A. Rowland, General counsel
43
SEC EDGARCynthia J. Ladd, General counsel
44
gleifCytomX Therapeutics, Inc. is founded